Compare BWEN & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | XLO |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 41.8M |
| IPO Year | N/A | 2021 |
| Metric | BWEN | XLO |
|---|---|---|
| Price | $3.58 | $0.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $2.00 |
| AVG Volume (30 Days) | 263.3K | ★ 305.9K |
| Earning Date | 03-04-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $153,877,000.00 | $31,804,000.00 |
| Revenue This Year | $11.68 | $626.78 |
| Revenue Next Year | N/A | $79.08 |
| P/E Ratio | $15.55 | ★ N/A |
| Revenue Growth | N/A | ★ 588.40 |
| 52 Week Low | $1.41 | $0.62 |
| 52 Week High | $4.15 | $1.70 |
| Indicator | BWEN | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 39.17 |
| Support Level | $3.32 | $0.63 |
| Resistance Level | $4.15 | $0.74 |
| Average True Range (ATR) | 0.29 | 0.03 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 56.99 | 10.01 |
Broadwind Inc is a precision manufacturer of structures, equipment and components for clean technology and other specialized applications. The company provide technologically high value products to customers with complex systems and stringent quality standards that operate in energy, mining and infrastructure sectors, in the United States of America. It capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treat, assembly, engineering and packaging solutions. It operates through four operating segments namely Heavy Fabrications, Gearing, Industrial Solutions and Corporate.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.